Recent events
Recent events tied to this brand in public sources.
Back to profile2 entries
2022
Nuance Pharma and Bavarian Nordic sign RSV vaccine license and supply agreement
Nuance Pharma and Bavarian Nordic signed an exclusive license and supply agreement covering development and commercialization of the MVA-BN RSV vaccine in mainland China, Hong Kong, Macau, Taiwan, South Korea and parts of Southeast Asia. Nuance Pharma will bear development, registration and commercialization costs in the covered territories; Bavarian Nordic will undertake commercial production and supply.
2019
Bavarian Nordic announced an agreement to sell its Priority Review Voucher
Bavarian Nordic announced an agreement to sell its Priority Review Voucher for USD 95 million. The buyer was not disclosed, and the transaction remained subject to customary closing conditions, including antitrust review.